Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;29(4):867-878.
doi: 10.1007/s11136-019-02367-7. Epub 2019 Nov 27.

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

E Charton  1   2 , B Cuer  3   4 , F Cottone  5 , F Efficace  5 , C Touraine  3 , Z Hamidou  6   7 , F Fiteni  3   8 , F Bonnetain  9   10   7 , M-C Woronoff-Lemsi  10   11 , C Bascoul-Mollevi  3   4   7 , A Anota  9   10   7
Affiliations

Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review

E Charton et al. Qual Life Res. 2020 Apr.

Abstract

Purpose: The time to deterioration (TTD) approach has been proposed as a modality of longitudinal analysis of patient-reported outcomes (PROs) in cancer randomized clinical trials (RCTs). The objective of this study was to perform a systematic review of how the TTD approach has been used in phase III RCTs to analyze longitudinal PRO data.

Methods: A systematic literature search was conducted in PubMed/MEDLINE, the Cochrane Library and through manual search to identify studies published between January 2014 and June 2018. All phase III cancer RCTs including a PRO endpoint using the TTD approach were considered. We collected general information about the study, PRO assessment and the TTD approach, such as the event definition, the choice of reference score and whether the deterioration was definitive or not.

Results: A total of 1549 articles were screened, and 39 studies were finally identified as relevant according to predefined criteria. Among these 39 studies, 36 (92.3%) were in advanced and/or metastatic cancer. Several different deterioration definitions were used in RCTs, 10 studies (25.6%) defined the deterioration as "definitive", corresponding to a deterioration maintained over time until the last PRO assessment available for each patient. The baseline score was explicitly stated as the reference score to qualify the deterioration for most studies (n = 31, 79.5%).

Conclusion: This review highlights the lack of standardization of the TTD approach for the analysis of PRO data in RCTs. Special attention should be paid to the definition of "deterioration", and this should be based on the specific cancer setting.

Keywords: Patient-reported outcomes; Randomized clinical trials; Systematic review; Time to deterioration.

PubMed Disclaimer

References

    1. Efficace, F., Fayers, P., Pusic, A., Cemal, Y., Yanagawa, J., Jacobs, M., et al. (2015). Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials. Cancer,121(18), 3335–3342. https://doi.org/10.1002/cncr.29489 . - DOI - PubMed - PMC
    1. Secord, A. A., Coleman, R. L., Havrilesky, L. J., Abernethy, A. P., Samsa, G. P., & Cella, D. (2015). Patient-reported outcomes as end points and outcome indicators in solid tumours. Nature Reviews. Clinical Oncology,12(6), 358–370. https://doi.org/10.1038/nrclinonc.2015.29 . - DOI - PubMed
    1. Bonnetain, F., Fiteni, F., Efficace, F., & Anota, A. (2016). Statistical challenges in the analysis of health-related quality of life in cancer clinical trials. Journal of Clinical Oncology,34(16), 1953–1956. https://doi.org/10.1200/JCO.2014.56.7974 . - DOI - PubMed
    1. Cnaan, A., Laird, N. M., & Slasor, P. (1997). Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Statistics in Medicine,16(20), 2349–2380. - DOI
    1. Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials. London: Chapman and Hall/CRC. - DOI

Publication types

LinkOut - more resources